Cryotherapy to Prevent Taxane-induced Sensory Neuropathy of the Hands and Feet
Cryotherapy to Prevent Taxane-induced Sensory Neuropathy of the Hands and Feet
Researchers are investigating the effectiveness and tolerability of cryotherapy and to
 evaluating whether it can prevent or improve taxane-induced sensory peripheral neuropathy.
Inclusion Criteria:

 -  Patients ≥18 years of age with a diagnosis of breast cancer

 -  Patients receiving 12-18 weeks of chemotherapy with a taxane-based regimen (4 cycles
 of weekly x3 paclitaxel or 4-6 cycles of docetaxel every 3 weeks)

 -  Absence of sensory peripheral neuropathy, skin or nail disorders at the start of
 treatment

 -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.

 -  Ability to complete questionnaires by themselves or with assistance.

 -  Ability to give signed informed consent

 Exclusion Criteria:

 -  History of prior sensory/motor peripheral neuropathy from any cause

 -  History of prior Raynaud's phenomenon

 -  History of cryoglobulinemia

 -  Active peripheral vascular disease

 -  Cold intolerance

 -  Prior exposure to neurotoxic chemotherapy

 -  Hand-foot syndrome

 -  Tumor metastasis in bone, soft tissue, or skin of the hands or feet

 -  Absence of one or more fingers or toes

 -  Prior exposure to taxane chemotherapy